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SUMMARY 
  Colorectal adenomas are cancer precursor lesions of the large bowel. A 
multitude of genomic and epigenomic changes have been documented in these preinvasive 
lesions, but their impact on the protein effectors of biological function has not been 
comprehensively explored. Using shotgun quantitative MS, we exhaustively investigated 
the proteome of 30 colorectal adenomas and paired samples of normal mucosa. Total 
protein extracts were prepared from these tissues (prospectively collected during 
colonoscopy) and from normal (HCEC) and cancerous (SW480, SW620, Caco2, HT29, 
CX1) colon epithelial cell lines. Peptides were labeled with isobaric tags (iTRAQ 8-plex), 
separated by OFFGEL electrophoresis, and analyzed by LC-coupled tandem MS. Non-
redundant protein families (4325 in tissues, 2017 in cell lines) were identified and 
quantified. Principal component analysis of the results clearly distinguished adenomas from 
normal mucosal samples, and cancer cell lines from HCEC cells. Two hundred twelve 
proteins displayed significant adenoma-related expression changes (q-value < 0.02, mean 
fold change vs. normal mucosa  +/-1.4), which correlated (r=0.74) with similar changes 
previously identified by our group at the transcriptome level. Fifty-one (~25%) proteins 
displayed directionally similar expression changes in colorectal cancer cells (vs. HCEC 
cells) and were therefore attributed to the epithelial component of adenomas. Although 
benign, adenomas already exhibited cancer-associated proteomic changes: 69 (91%) of the 
76 protein upregulations identified in these lesions have already been reported in cancers. 
One of the most striking changes involved sorbitol dehydrogenase (SORD), a key enzyme 
in the polyol pathway. Validation studies revealed dramatically increased SORD 
concentrations and activity in adenomas and cancer cell lines, along with important 
changes in the expression of other enzymes in the same (AKR1B1) and related (KHK) 
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pathways. Dysregulated polyol metabolism may represent a novel facet of the metabolome 
remodeling associated with tumorigenesis. 
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INTRODUCTION 
Colorectal cancer ranks third among the world’s high-incidence cancers and is a 
leading cause of cancer-related death among older adults (1, 2). In the United States alone, 
projections for 2013 include 102,480 new cases and 50,830 deaths (2). Cancerogenesis in 
the large bowel begins with the transformation of the epithelial cell lining of the gut. 
Molecular alterations, mainly involving the WNT signaling pathway, render these cells 
hyperproliferative, and they form benign adenomatous tumors. The neoplasms are initially 
noninvasive (3, 4), and the vast majority remain that way. But as genetic and epigenetic 
anomalies continue to accumulate, the tumor cells’ capacity for invasion and destruction of 
surrounding tissues increases. At some point, this process drives certain adenomas into the 
realm of frank malignancy, transforming them into adenocarcinomas.  
Early diagnosis of colorectal tumors has been greatly facilitated by screening 
methods based on fecal analysis or colonoscopy, but both approaches have limitations (5-
9). Better understanding of the molecular mechanisms underlying large bowel 
tumorigenesis could improve our chances of detecting these lesions in the adenomatous or 
localized adenocarcinomatous stage, when the chances of successful treatment are 
greater. Promising results for the detection and validation of potential cancer biomarkers 
are emerging from proteomic studies of cancer development (10). Compared with older gel 
electrophoresis-based approaches, shotgun proteomic methods, particularly those that 
include pre-MS OFFGEL electrophoretic peptide fractionation (11), enhance the sensitivity, 
robustness, and reproducibility of these studies (12) and expand the proteome coverage to 
include proteins that are less abundantly expressed (13-16). Furthermore, with the aid of 
isobaric-tag peptide labeling strategies, MS can also be used for relative quantification of 
protein expression levels within a series of multiple human tissue samples (12, 17-19).  
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Thus far, only a few MS-based proteomic studies have examined human 
colorectal adenomas (reviewed in refs. (9, 20)). We therefore decided to explore the 
proteome of a relatively large series of these precancerous lesions (each with a paired 
sample of normal colon mucosa) using quantitative shotgun MS with the widely used 
iTRAQ (isobaric tags for relative and absolute quantitation) peptide labeling technique (21, 
22) and OFFGEL fractionation. Adenoma-related protein expression variations specific to 
the epithelial compartment of these lesions were identified with a novel approach, which 
involved comparing the human tissue proteome with that of colon epithelial cell lines. The 
results of these studies revealed several protein expression changes previously 
documented only in advanced colorectal cancers. They also disclosed several novel 
changes with potentially important roles in early-stage large bowel tumorigenesis, including 
the marked upregulation of a key enzyme in the polyol pathway.  
 
EXPERIMENTAL PROCEDURES 
Human tissue samples and cell lines 
Human colorectal tissues were prospectively collected from patients undergoing 
colonoscopy in the Istituti Ospitalieri of Cremona, Italy. Local ethics committee approval 
was obtained, and tissues were used in accordance with the Declaration of Helsinki. Each 
donor provided written informed consent to sample collection, data analysis, and publication 
of the findings. Progressive numbers were assigned to each patient to protect human 
confidentiality. The series comprised 30 colorectal adenomas, each with a paired sample of 
normal mucosa from the same colon segment, >2 cm from the lesion. Tissues were 
collected endoscopically, promptly frozen in liquid nitrogen, and stored at -80 oC. 
Five colorectal cancer cell lines (HT29, Caco2, CX1, SW480, SW620) were 
obtained from the Zurich Cancer Network's Cell Line Repository. All had been recently 
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purchased from the American Tissue Culture Collection (Teddington, UK) and were certified 
to be mycoplasma infection-free. Caco2 and CX1 cells were cultured in Dulbecco's 
Modified Eagle Medium, HT29 cells in McCoy's medium, and SW480 and SW620 cells in 
RPMI 1640 medium supplemented with 10% fetal bovine serum, L-glutamine, and 1% 
penicillin-streptomycin (Sigma, St Louis, Missouri, USA). The recently established line of 
immortalized human colon epithelial cells (HCEC) was obtained from J. W. Shay and grown 
as described elsewhere (23). 
Protein extraction from tissues and cell lines 
For MS studies, frozen tissue samples were quickly weighed and homogenized on 
ice (1 min grinding, 1 min on ice, 1 min grinding) in a Wheaton glass borosilicate grinder 
containing a solution of 100 mM triethylammonium bicarbonate (Sigma, St Louis, MO, 
USA), 1X Complete EDTA-free Protease Inhibitor Cocktail (Roche, Mannheim, Germany), 1 
M urea, 5 mM β-glycerophosphate disodium salt hydrate, 1 mM sodium orthovanadate, and 
5 mM sodium fluoride (Sigma). The efficiency of cell lysis was microscopically confirmed. 
The homogenates were then sonicated with a Bioruptor (Diagenode, Denville, NJ, USA) 
(high power, five 10''/10'' ON/OFF cycles) and centrifuged (16,000g for 5 min at 4 oC). The 
supernatant containing the proteins was collected and stored at -80 oC.   
Cells (grown to >80% confluence in 15 cm2 dishes) were washed in PBS, covered 
with 250 µL of the buffer used for tissue sample homogenization (see above), detached 
from the dish with a cell scraper, and homogenized (25 passages through a 25G needle). 
The efficiency of cell lysis was microscopically confirmed. Sonication and centrifugation 
were repeated, as described above, and the protein concentration was determined by 
Bradford assay. Prior to MS analysis, a 5-µg sample of each protein extract was subjected 
to 1-dimensional gel electrophoresis on a 12% bisacrylamide gel to assess protein integrity 
and extraction protocol reproducibility. The entire proteomic workflow, from tissue/cell 
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processing to statistical analysis, is summarized in Figure 1 and described in detail in the 
next five sections of Experimental procedures. 
For sorbitol dehydrogenase (SORD) assays (see below), >80% confluent cells 
were washed in PBS and covered with a solution consisting of 100 mM triethanolamine 
(Sigma) and 1X Complete EDTA-free Protease Inhibitor Cocktail (Roche). (A simple buffer 
was used to reduce the risk of introducing anti-enzymatic substances into our extract.) Cells 
were then scraped and homogenized with 25 passages through a 25G needle. Tissue 
samples were weighed and homogenized in a Wheaton glass borosilicate grinder 
containing the buffer described above. After centrifugation (16,000 g, 4 oC, 5 min), the 
supernatant was aliquoted and stored at -80 oC. Protein concentration was measured by 
Bradford assay. 
Protein digestion and iTRAQ 8-plex labeling 
iTRAQ 8-plex experiments were performed to analyze tissue extracts (10 
experiments) and cell-line extracts (1 experiment) (Figure 1). Labeling efficiency and 
relative quantitation accuracy were assessed with the aid of two reference protein extract 
mixtures: one for tissue samples (pooled extracts from 3 normal tissues and 3 adenomas) 
and one for cell lines (pooled aliquots of each of the six cell line extracts). Fifty micrograms 
of protein per sample were used for each iTRAQ channel. Tryptic digestion (10% w/w, 
sequencing-grade modified trypsin; Promega, Madison, WI, USA) and iTRAQ 8-plex 
labeling (AB Sciex, Framingham, MA, USA) were performed according to manufacturers’ 
instructions (2.5-hour incubation of samples with iTRAQ labels). For tissue experiments, 
two iTRAQ labels, 113 and 114, were chosen for the reference mixture, while labels 
115/116, 117/118, and 119/121 were used for the 3 pairs of normal/adenomatous tissues 
included in each experiment. For the cell line experiment, labels 113 and114 were used for 
the reference mixture, and labels 115-121 represented HCEC, HT29, Caco2, CX1, SW480, 
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and SW620 cells, respectively (Figure 1). After iTRAQ labeling, the samples (for each 
experiment) were combined, desalted on 500 mg SepPak C18 columns (Millipore, Billerica, 
MA, USA), dried in a SpeedVac concentrator (Thermo Scientific, NC, USA), and subjected 
to peptide fractionation. 
OFFGEL electrophoresis 
Peptide fractionation was performed according to the manufacturer’s protocols 
with an Agilent 3100 OFFGEL fractionator and 12-well OFFGEL kit (both from Agilent 
Technologies, Santa Clara, CA, USA). Briefly, samples were resolubilized in 1.8 mL of 1x 
OFFGEL peptide stock solution containing carrier ampholytes (pH range 3–10), loaded into 
the wells (150 µL per well), and focused until 20 kV/h was reached with a maximum current 
of 50 µA. For each experiment, 12 fractions were collected. A 15-µL aliquot of each fraction 
was acidified with 1.5 µL of a 50% acetonitrile / 1% trifluoroacetic acid solution, desalted 
using ZipTip C18 (Millipore, Billerica, MA, USA), dried, resolubilized in 15 µL of a 0.1% 
formic acid / 3% acetonitrile solution, and analyzed with MS.  
Liquid Chromatography and Mass Spectrometry  
Peptide samples (4 µL) were analyzed on an LTQ-Orbitrap Velos mass 
spectrometer (Thermo Fischer Scientific, Bremen, Germany) coupled to a nano-HPLC 
system (Eksigent Technologies, Dublin, CA, USA). The solvent compositions were 0.2% 
formic acid and 1% acetonitrile for channel A and 0.2% formic acid and 80% acetonitrile for 
channel B. Peptides were loaded onto an in-house-made tip column (75 µm × 80 mm) 
packed with reverse-phase C18 material (AQ, 3 µm 200 Å, Bischoff GmbH, Leonberg, 
Germany) and eluted (flow rate, 250 nL/min; solvent B gradient: from 3% to 30% in 62 min, 
from 30% to 45% in 70 min, and 45% to 97% in 75 min).  
Full-scan MS spectra (300−1700 m/z) were acquired at a resolution setting of 
30000 at 400 m/z after accumulation to a target value of 1 x 106. For the eight most intense 
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signals per cycle above a threshold of 1000, both CID (collision-induced dissociation) and 
HCD (higher-energy collisional dissociation) spectra were acquired in a data-dependent 
manner (Figure 1). CID scans were recorded in the ion-trap (settings: normalized collision 
energy, 35; maximum injection time, 50 ms; automatic gain control [AGC], 1 x 104 ions). For 
the HCD scans, spectra were recorded at a resolution setting of 7500 at 400m/z 
(normalized collision energy, 52; maximum injection time, 125 ms; AGC, 5 x 104 ions). 
Charge state screening was enabled, and singly charged states were rejected. Precursor 
masses previously selected for MS/MS were excluded from further selection for 60 s, and 
the exclusion window was set at 10 ppm. The maximum number of entries in the exclusion 
list was set at 500. All samples were analyzed in duplicate, and precursors selected in the 
first run were excluded from fragmentation in the second run. The exclusion list was set on 
a time window of 4 minutes and mass width of 10 ppm. Spectra were acquired using 
internal lock mass calibration on m/z 429.088735 and 445.120025. 
Peak list generation and database search 
As depicted in Figure 1, Mascot Distiller 2.4.3.3 (Matrix Science, Boston, MA, 
USA) was used to generate Mascot generic format (MGF) peak lists. De-isotoping and peak 
picking were not performed between 112.5 and 121.5 m/z (the range containing iTRAQ 
reporter ions), and the HCD and CID spectra were merged by summing. For each of the 11 
experiments, the corresponding 24 MGF peak lists were concatenated and searched, with 
the aid of the Mascot Server 2.3.02 (Matrix Science), against a forward UniProtKB/Swiss-
Prot database for human proteins concatenated to a reversed decoyed FASTA database. 
The concatenated database contained a total of 147,438 proteins with accessions in Gene 
Ontology-compatible format and 260 common MS contaminants (NCBI taxonomy ID 9606, 
release date 2011-12-13). 
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Methylthio (C), iTRAQ 8-plex labeling at N-terminal and lysine were set as fixed 
modifications, while variable modifications consisted of methionine oxidation and iTRAQ 8-
plex labeling of tyrosine. We used the iTRAQ 8-plex-vs114 (Applied Biosystems) 
quantitation method. The isotope and impurity correction factors used for each iTRAQ label 
were those provided by the manufacturer. Precursor and fragment tolerances were set at 
10 ppm and 0.8 Da, respectively. Enzyme specificity was set to trypsin with an allowance of 
up to 1 missed cleavage. Using Mascot internal export scripts, we transformed Mascot DAT 
files into XML files and parsed them with in-house scripts so that peptide sequences, 
scores, and intensities of the individual reporter ion channels were reported. Confidently 
identified and quantified peptides were selected with the following filters: rank 1 (best 
spectra assignment); ion score: > 15; and presence of iTRAQ intensity values for reporter 
channels 113 and 114. 
Quantification of relative protein abundance (steps described in the boxes of the lower half 
of Figure 1) 
Peptide reporter channel intensities were summed for each protein individually 
using R-scripts. Ratios were built from summed channels (113/114 to 121/114) for all 
proteins identified in each iTRAQ experiment. False discovery rates (FDRs) (24) were 
determined at the spectrum, peptide, and protein levels. The results of individual 
experiments were then merged into one matrix, which was used for statistical analysis in R 
and Perseus (Version 1.2.7.4). All proteins identified with the same peptide(s) were 
grouped into families, each of which was identified by a unique protein family number. 
Ratios of the intensity of each ion channel to that of 114 were converted to base 2 
logarithmic values and normalized respectively on the median (which was set at 0), 
resulting in ratios that followed a Gaussian distribution. Proteins identified on the basis of 
the same peptide(s) shared the same family number and were represented once in our 
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statistical analysis. The paired t-test was used to compare the expression of a given protein 
in each adenoma and that found in the corresponding sample of normal mucosa. To correct 
for multiple comparisons, the FDR was controlled with the Benjamini-Hochberg procedure. 
The average protein-expression fold change in adenomas, compared with the normal 
mucosa, was then calculated. For this, median normalized ratios for all proteins in each 
paired adenoma-normal mucosa sample were deconvoluted of the reference standard 
effects (114) to compute the adenoma vs. normal mucosa ratio per protein (deconvoluted 
fold change, i.e.[116/114] / [115/114] = [116/115]) and the mean fold change per protein in 
all tissue pairs. The Mascot emPAI value for all proteins were included in XML exports for 
each experiment. Thereafter, the mean Mascot emPAI value was calculated for all proteins. 
Functional annotation of proteins 
Gene ontology (GO) annotations and GO terms for proteins in the 
UniProt/SwissProt database were sourced from http://www.ebi.ac.uk/. The Scaffold 
program (Version 3) was used to identify the cellular localizations and biological processes 
most represented in lists of proteins quantified in tissues and cell lines. The topGO 
Bioconductor software package in R was used to identify and screen for GO biological 
process categories displaying enrichment for proteins that were differentially regulated in 
adenomas (vs. normal mucosa) (25). First, we prepared a "Universe" comprising all the 
proteins quantified in our study, each matched to GO terms and annotations. This served 
as the "Background." The "Foreground" consisted of the list of significantly dysregulated 
proteins. The most significant GO terms were scored with the Eliminating Genes (elim) 
method (25).  
Western Blotting 
Proteins were separated on a 10% SDS-polyacrylamide gel and transferred to a 
hydrophobic polyvinylidene difluoride membrane (GE Healthcare, Amersham Hybond-P 
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PVDF membrane, Pittsburgh, PA, USA) according to standard protocols (26). After 1 h of 
blocking with 5% non-fat dry milk in TBS with 1% Tween 20 (milk-TBST), membranes were 
incubated overnight with the primary antibody (anti-SORD [HPA040260 Sigma]; anti-aldose 
reductase, AKR1B1 [GTX113381 GeneTex]; anti-ketohexokinase, KHK [GTX109591 
GeneTex]) diluted 1:1000 in milk-TBST, washed once with milk-TBST (20 min) and twice 
with TBST (20 min). After 1 h of incubation in horseradish peroxidase-conjugated 
secondary antibody (anti-rabbit IgG, GE Healthcare) diluted 1:5000 in milk-TBST, 
membranes were washed once with milk (20 min) and twice with TBST (20 min). Enhanced 
chemiluminescence (ECL, Amersham Pharmacia Biotech, Cat. No. RPN2106) was used to 
detect immunoreactive proteins. 
Immunostaining of cells and tissues 
HT29 and HCEC cells were seeded (3 x 105 per well) on 22 x 22 mm cover slips 
in 6-well plates and grown under standard conditions until cells reached 70-80% 
confluence. Cells were then washed twice with PBS and fixed in ethanol:methanol solution 
(50:50) for 10 min at room temperature. Fixed cells were permeabilized (10 min with 0.25% 
Triton X-100), blocked (30 min in 10% goat serum [X0907, Dako, Glostrup, Denmark]), and 
incubated with primary antibody (rabbit polyclonal anti-SORD, HPA040260, Sigma, 1:100) 
for 18 h at 4 oC. After three washes with PBS, the cells were incubated for 1 h with 
secondary antibody conjugated to polymer-HRP anti-rabbit (Dako, EnVision+ System- 
HRP; Cat. No. K4010). They were then washed three times in PBS and incubated for 15 
min in the substrate-chromogen, 3,3-diaminobenzidine tetrahydrochloride (DAB, Dako, 
EnVision+ System- HRP; Cat. No. K4010). Cells were washed quickly with PBS and 
mounted on slides (EUKITT, O. Kindler, GmbH, Freiburg, Germany) for light microscopy 
(Leica Microsystems GmbH, Wetzlar, Germany). Images were examined and recorded with 
Leica Application Suite (V3.3.0) software. 
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Sorbitol dehydrogenase immunohistochemistry was performed as previously 
described (27). Tissue sections (normal colon and ileum, colorectal adenomas and 
adenocarcinomas) were incubated for 24 h at 4 oC with primary antibody (rabbit polyclonal 
anti-SORD, HPA040261, Sigma) at a 1:100 dilution.  
Measurement of SORD activity 
Total protein was extracted from cell lines and tissues as described above. SORD 
catalyzes the reversible conversion of D-sorbitol to D-fructose, with β-NADH as a cofactor: 
D-fructose + β-NADH <--------------> D-sorbitol + β-NAD 
            SORD 
 
SORD activity was quantified via continuous spectrophotometric rate measurement of the 
β-NAD formation rate (temperature 25 oC, pH 7.6, A340nm, light path of 1 cm) in a Cary 50 
Scan UV-visible spectrophotometer using the Cary Kinetics Application (both from Varian 
Inc., Palo Alto, CA, USA) (28). The final reagent concentrations in a 1-mL cuvette were as 
follows: 78.33 mM triethonolamine, 183 mM D-fructose, 0.21 mM β-NADH, 0.033% (w/v) 
BSA. The absorbance reading was recorded when the enzyme was added. One unit of 
enzyme activity was defined as the amount of enzyme required per minute to convert 1.0 
µmole of D-fructose to D-sorbitol at pH 7.6 at 25 oC. A mixture of reagents plus recombinant 
SORD was used as the positive control; negative controls consisted of the same reagent 
mixture with no recombinant SORD, with recombinant SORD but no D-fructose, or with 
recombinant SORD but no β-NADH.  
Extraction and quantification of intracellular metabolites by targeted gas chromatography-
coupled MS  
Frozen tissue (50 to 100 mg) was homogenized in 250 µl ice-cold 80% methanol 
using a glass borosilicate grinder from Wheaton. The homogenate was microscopically 
examined to ensure that it was cell-free and then transferred to Eppendorf vials and left on 
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ice for 15 min to ensure efficient protein precipitation. After centrifugation (15,000g for 3 min 
at 0 oC), the supernatant was snap-frozen and stored at -80 oC, while the protein content of 
the pellet was determined by the Bradford method. 
For gas chromatography-coupled MS (GC-TOF-MS) analyses, 10 µL of 
supernatant was transferred to a 1.5-mL Eppendorf tube, and internal standards (13C1-
sorbitol, 13C1-fructose, and 13C1-glucose—1.2 pmoles of each) were added. The samples 
were then dried overnight in a vacuum centrifuge (Concentrator 5301, Eppendorf AG, 
Germany). Methoxyamine hydrochloride and N-methyl-N-(trimethylsilyl)trifluoroecetamide 
were used as derivatization reagents (29).  
The derivatized metabolites and internal standards were subjected to GC-TOF-
MS (GC 7890A, Agilent Technologies, Santa Clara, CA, USA; GCT Premier Micromass, 
Waters, Manchester, UK) with a Rxi-5Sil MS Integra-Guard column (length: 30 meters, 
internal diameter: 0.25 mm) and a film thickness of 0.25 µm (Restek, USA). One microliter 
of each derivatized sample was injected in splitless mode on a baffled glass liner and 
transferred to the capillary column by rapid heating of the liner from 50 oC to 250 oC at a 
rate of 12 oC/sec. For the separation of the metabolites, helium was used at a flow rate of 1 
ml/min and, after an initial hold time of 2 min, a temperature gradient from 80 oC to 320 oC 
(rate 8 oC/min) was applied. The TOF-MS was set to acquire centroided standard electron 
ionization mass spectra over a range of 50 to 600 m/z at a rate of 3 spectra/sec. The GC-
MS transfer line was heated to 280 oC. Dynamic range enhancement was activated. C6ClF5 
was used as lock mass compound. 
The MassLynx and QuanLynx programs (Waters, UK) were used to review and 
analyze the acquired data. The absolute concentrations of D-sorbitol, α and β D-fructose, 
and α and β D-glucose were calculated on the basis of the ratio of the intensity of specific 
fragments originating from the unlabeled compound to that of the added labeled analogue 
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(internal standard). These concentrations were used to estimate intracellular levels per 
milligram of tissue (adenoma vs. normal mucosa). The relative concentration of lactate was 
estimated from the ratio of the intensity of specific fragments originating from the unlabeled 
compound and that of the added 13C1-sorbitol (internal standard). 
 
RESULTS 
Proteomic analysis of human colorectal tissues and colon cell lines. 
We used a quantitative-MS-based discovery strategy to explore the proteome of 
human colorectal tissues and colon cell lines (normal and neoplastic). The characteristics of 
the precancerous colorectal lesions are listed in Table 1. Protein extracts from these tumors 
and their paired samples of normal mucosa (total, 60 samples) were analyzed using iTRAQ 
LC-MS/MS and the workflow described in Figure 1. The inclusion of two reference sample 
mixes allowed us to control for technical variability across the ten experiments on tissue 
samples since the reference sample was analyzed twice in each experiment. OFFGEL 
electrophoresis was used to obtain highly reproducible, pI-based, in-solution separation of 
pooled iTRAQ-labeled peptides. Furthermore, for relative quantification of proteins using 
iTRAQ reporter ions, we adopted a stringent FDR for protein spectra matches (PSMs), and 
high-confidence peptides for protein quantification were selected only if the reporter ions 
(113 and 114) were quantified in the reference sample mix (iTRAQ reporter channels 113 
and 114). The data set generated with this approach was large and complex, but we 
developed a simplified analytical method that allowed us to work with and merge the large 
data files generated after MS/MS (Figure 1). High-resolution MS/MS spectra acquired on 
the LTQ-Orbitrap Velos spectrometer after duplicate analysis of OFFGEL tissue sample 
fractions produced a total of 240 raw files (10 experiments, 120 fractions, 2 replicates). A 
total of 37,184 (FDR = 0.9%) unique tryptic peptides were confidently identified and 
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quantified from 285,929 unique PSMs (FDR = 0.2%) (Table 2, Supplementary Table 1). 
Ten thousand four hundred fifty-two proteins (FDR = 1.5%) were assembled from the 
quantified peptides. Proteins that were indistinguishable by MS/MS (i.e., two or more 
proteins identified on the basis of the same peptide sequence; see Experimental 
procedures for details) were represented as a single family. The result was a total of 4325 
non-redundant protein families, two-thirds (2865, 66%) of which were relatively quantified in 
at least 9 normal mucosa/adenoma pairs and 1072 (25%) in all 30 pairs (Table 2, 
Supplementary Table 1).  
To verify the efficiency of iTRAQ protein labeling, we repeated the database 
search with Methylthio (C) set as a fixed modification and iTRAQ8plex (N-term), 
iTRAQ8plex (K), iTRAQ8plex (Y), and Oxidation (M) set as variable modifications. (All other 
search parameters were unchanged.) The assigned PSMs were filtered, as described in 
Experimental procedures, and the average iTRAQ labeling efficiency achieved in each of 
the 10 tissue experiments was 96% (Supplementary Table 2). To ascertain the efficacy of 
including a standard sample mix as a reference for normalization, we compared combined 
Gaussian plots of log2-protein ratios of normal mucosa or adenoma samples with the 
respective reference channel per experiment (e.g., 115/114 vs. 113/114 for normal tissues, 
116/114 vs. 113/114 for adenomas, see Figure 1). The ratios displayed normal distributions 
in all channels. For the reference channel (113/114), log2-ratios were largely centered 
around 0, whereas the distribution of adenoma and normal channel log2-ratios was broader 
and not always centered at 0 (data not shown).  
Sample complexity is a common problem in the analysis of proteomic data from 
human colorectal tissues. It stems in part from contamination of the epithelial cell proteome 
by proteins from stromal cells (which were inevitably present in our specimens even though 
the endoscopic tissue sampling procedure we used yielded superficial specimens with 
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consistently high epithelial contents). Microdissection can be utilized to isolate 
subpopulations of cells, but it can diminish the quantity and quality of the proteins, 
rendering them suboptimal for some types of proteomic analysis. To avoid this problem, we 
adopted a novel strategy for preliminary identification of the proteomic alterations that were 
most likely to involve the epithelial-cell component of the adenomas. The proteomic profiles 
of the colon tissues were compared with those of six colon epithelial cell lines (five colon 
cancer cell lines plus HCEC cells, to our knowledge, the only well-characterized line 
established from normal colorectal epithelium (23)). Changes in expression levels observed 
in adenomas (i.e., upregulation or downregulation with respect to normal mucosal levels) 
were presumed to be epithelial-cell-specific if similar changes were found in the colon 
cancer cell lines (relative to HCEC cells). After OFFGEL fractionation, duplicate MS 
analysis of iTRAQ-labeled peptides (24 fractions) from the six cell lines was performed in 
an LTQ-Orbitrap Velos mass spectrometer, and 11,266 peptides (FDR = 0.5%) were 
confidently identified and quantified from 27,922 unique PSMs (FDR = 0.4%) (Table 2, 
Supplementary Table 3). A total of 2017 non-redundant protein families (FDR = 1.1%) were 
identified and relatively quantified in cell lines; 1957 (97%) were present in all six cell lines 
(Table 2). In the iTRAQ experiment with cell lines, peptide labeling efficiency was 95% 
(Supplementary Table 2).  
Relative quantification of the proteomes of colorectal tissues and cell lines. 
The concentration range for proteins expressed in human tissues spans ten 
orders of magnitude. We chose not to deplete our protein samples of high-abundance 
proteins (e.g., albumin, IgG), because with the number of tissue samples being analyzed, 
additional sample preparation steps were considered potential sources of confounding 
variability (30). As an alternative, each of the ten pooled iTRAQ-labeled samples (ten 
experiments) were separated into 12 fractions based on the isoelectric point of peptides, 
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reducing the complexity of our protein matrix and limiting the risk of a bias toward the more 
abundant proteins.  
The expression levels of the 4325 non-redundant protein families we were able to 
relatively quantify in colorectal tissues spanned four orders of magnitude, as deduced from 
the protein Mascot emPAI value (used as a proxy for the emPAI value (31) to estimate 
protein concentrations) (Figure 2A). Thirty percent (1304/4325) of these families were 
relatively quantified on the basis of more than one unique peptide. At the top of this list 
were the large proteins AHNAK, DYNC1H1, DSP, and FCGBP (Figure 2B). In colon 
epithelial cell lines, 1174 of the 2017 protein families were relatively quantified with more 
than one unique peptide. 
Gene Ontology Annotation in Scaffold was used to identify the subcellular 
localizations of these protein families and the biological processes they were involved in. 
The GO categories represented in the tissue and cell line proteomes were fairly similar. In 
the cell-line proteome, however, the categories generally contained fewer proteins since the 
total number of proteins detected in these cells was lower than that of the tissues (Figure 
2C). Cytoplasmic and organelle- or membrane-associated proteins were the most highly 
represented categories in our extracts, but nuclear proteins were also readily identified, 
which indicates that our protein extraction procedure was not strongly biased toward a few 
cell compartments. The most highly represented biological processes in the tissue 
proteome were metabolic or biosynthetic processes, whereas cell component organization 
and developmental processes predominated in the cell line proteome (Figure 2D). Stromal 
contamination is probably responsible for the increased representation of immune system 
processes in the tissue proteome (compared with that of the cell lines).  
Log2-expression levels of the protein families identified in all tissues (n=1072) and 
cell lines (n=1957) (Table 2) were subjected to principal component analysis (PCA), which 
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easily distinguished the adenomas from the normal mucosa samples (Figure 3A) and the 
five colon cancer cell lines from the immortalized normal colon epithelial cell line HCEC 
(Figure 3B). The cancer cell lines were also segregated into three distinct groups reflecting 
their patient origins (Figure 3B). When PCA was performed on the expression intensity 
values of the 1496 non-redundant proteins expressed and quantified in all tissues and cell 
lines (i.e., those representing the intersection of the tissue [n=10,452] and cell-line [n=5056] 
protein sets reported in Table 2), colon cancer cell lines clustered with adenomas, while 
HCEC cells were closer to the normal mucosa samples (Figure 3C). 
 As a quality control measure, data for the 60 tissue samples (1072 protein 
families) were subjected to hierarchical clustering analysis. As shown in Supplementary 
Figure 1, three main clusters emerged: one consisting almost exclusively of normal mucosa 
samples, a second containing mainly adenomas, and a third that included both tissue types. 
The 18 samples in the third cluster (nine adenoma/normal mucosa pairs) formed three sub-
clusters, which corresponded to three of the 10 experiments for which trypsin digestion, 
iTRAQ labeling, and LC-MS/MS were performed on the same day. These findings were 
suggestive of an experimental bias. Indeed, when these 18 potentially sub-standard 
samples were included in subsequent statistical analyses, they diminished the stringency of 
our threshold and increased the error margin for false identification. We therefore excluded 
these samples from the analyses described in the following section.  
Proteins displaying dysregulated expression in colorectal adenomas and colon cell lines 
To identify proteins whose expression was significantly altered in adenomas 
(relative to normal mucosa), we analyzed data on the proteins quantified in the remaining 
21 tissue pairs. The experimentally derived protein fold-change threshold defining 
differential expression was based on comparison of the distributions of average intensity 
log2 ratios in the reference standard (113 vs. 114, seven experiments) and in patient 
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samples (adenoma vs. normal, seven experiments). The average ratios in the reference 
sample were centered around 1 (i.e., log2 0). Average fold-change ratios for the tissue 
samples displayed wider variance (Supplementary Figure 2). Seventeen percent of the log2 
ratios for the tissue samples exceeded ± 0.5 log2 scale (indicating a linear fold change of ≥ 
± 1.4) as opposed to only 5% of those for the reference samples.  For each protein, a 
paired t-test was used to compare the intensity ratios in normal and adenomatous samples 
(i.e., normal/114; adenoma/114). After adjustment for multiple comparison (Benjamini-
Hochberg method), we selected a stringent q value cutoff of ≤ 0.02.  
The 212 proteins that satisfied this criterion and presented a mean expression fold 
change of ± 1.4 (log2 0.5) or more were classified as significantly dysregulated in 
adenomas. They included 76 with upregulated expression and 136 with downregulated 
expression in the tumor samples (Table 3). When protein abundance iTRAQ ratios for these 
212 proteins were plotted on a heat map, adenomas and normal mucosa samples formed 
two distinct clusters (Figure 4A). As shown in Figure 4B, tissue expression levels for the 
212 dysregulated proteins showed good correlation (r = 0.74, P < 0.001, 95% CI: 0.67 - 
0.79) with those of mRNAs for the same genes (measured by our group in another set of 
colorectal adenomas) (26). 
Table 4 lists the biological processes that were over-represented in this set of 
proteins. At the top of this list was xenobiotic metabolism, a process already linked with 
adenoma formation on the basis of enrichment studies of transcriptomic datasets 
conducted by our group (32). Three of the dysregulated proteins involved in this process 
(CYP2S1, NQO1, and GSTP1) displayed upregulated expression in adenomas, but most 
were characterized by tumor-related downregulation (ADH1B, ADH1C/ADH1A, 
UGT1A9/UGT1A6, UGT1A1/UGT1A4/UGT1A3/UGT1A5, UGT1A7/UGT1A8, UGDH, 
MAOA, SULT1A3/SULT1A1, PAPSS1/PAPSS2, UGP2). Network-building analysis 
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revealed that all these proteins were linked by sub-networks controlled by cancer-
associated transcription factors, such as SP1 or, less frequently, MYC, HIF1A, or TP53 
(Supplementary Figure 3). As noted in Table 4, a very similar picture emerged when gene 
ontology enrichment was also analyzed in a larger set of 621 dysregulated proteins 
selected with less stringent criteria (q value cut-off ≤ 0.2;  average log2 fold change ≥ ± 0.5). 
The expression levels of 111 (52%) of the 212 proteins that were differentially 
expressed in adenomas were also quantified in cell lines (those shown in boldface in Table 
3 and referred to hereafter as the "epithelial cell signature" proteins). Almost half (n=51, 
46%) showed directionally similar tumor-related dysregulation in both analyses. Since cell-
line studies were conducted with only one non-cancerous line, these findings obviously 
require further validation. They suggest, however, that these 51 proteins are indeed 
expressed in the epithelial cells of normal colorectal tissues and that their expression is 
dysregulated in the epithelial cells of adenomas.  
Upregulation of SORD expression and activity in colorectal adenomas and cancer cell lines 
Sorbitol dehydrogenase, a key enzyme in the polyol pathway, was one of the 
most significantly upregulated proteins in our colorectal adenomas (based on q values) 
(Table 3). Because its increased expression could have metabolic consequences with 
potential impact on tumorigenesis, we performed Western blotting and immunostaining 
studies to validate this finding. The reliability of the anti-SORD antibody we had chosen was 
first tested on protein extracts from the six colorectal epithelial cell lines (Figure 5A). The 
tumor-related log2 fold changes detected with Western blotting were substantially larger 
than those documented with iTRAQ (2 to 6 vs. 0.4 to 1, respectively) (Figure 5B), which 
was not surprising since iTRAQ has been reported to underestimate protein abundance 
(33). However, the relative quantities of SORD found with the two methods were fully 
consistent. As for the 21 adenomas, the elevated SORD expression documented in these 
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tumors by iTRAQ (Figure 5C) showed good correlation with the increased SORD mRNA 
levels we had previously found in other 42 lesions of this type (26) (Figure 5D). Western 
blot analysis of four randomly selected adenoma/normal mucosa pairs from the present 
series revealed obvious upregulation of SORD expression in all four tumors although the 
magnitude of the increase varied (Figure 5E).  
SORD activity was then assayed (see Experimental procedures) to see how it 
corresponded with the enzyme expression levels reported above. As shown in Figure 5F, 
the results of cell line assays were fully consistent with the Western blotting data: SORD 
activity was 7 times higher in HT29 than in HCEC cells, and more limited upregulation was 
found in SW480. High correlation between enzyme activity and protein level was also 
documented for three randomly selected adenoma/normal mucosa pairs (Figure 5F). 
MS and Western blotting findings were further validated with immunostaining 
studies, as shown in Figure 6. Cytoplasmic SORD staining was evident in the colon cancer 
cell line HT29 but weaker or even absent in normal epithelial HCEC cells (Figures 6A and 
6B). As for colorectal tissues, SORD cytoplasmic expression was limited to the bottom of 
the normal epithelial crypts (Figures 6C, 6D, and 6E), but its expression was markedly 
increased in adenomatous and cancerous glands (Figures 6F - 6I). These findings suggests 
that SORD is likely to be expressed in proliferating cells, although it was largely absent in 
HCECs, which undergo regular proliferation in vitro. Furthermore, nuclear localization of 
SORD was noted in some adenomatous crypts (Supplementary Figure 4A and C), and the 
cells in question were almost always negative for the well-known proliferation marker Ki-67 
(Supplementary Figure 4B and D). This mutually-exclusive staining pattern was also 
observed in normal crypts of the ileum where SORD, interestingly, appeared to be 
expressed in the nuclei of putative stem cells (Supplementary Figure 4E and F). 
Polyol pathway enzyme expression and metabolite levels in cell lines and tissues. 
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 We then examined the state of the polyol pathway (Supplementary Figure 5A) in 
colorectal cell lines and tissues. As shown in Supplementary Figure 5B, immunoblot studies 
revealed decreased AKR1B1 expression in HT29 (vs. HCEC cells) and adenomas (vs. 
corresponding normal mucosal samples), while SORD expression and that of KHK were 
upregulated in tumor cells and tissues. As for the metabolites (Supplementary Figure 5C), 
D-glucose levels were significantly decreased in adenomas. Less dramatic changes were 
observed in the levels of D-sorbitol and D-fructose, which both showed a tendency to 
decrease in tumor tissues.  
 
DISCUSSION  
  Although a number of proteomic studies have comparatively analyzed different 
types of colorectal tissues, precancerous lesions have been considered in only three (21, 
34, 35), and in two of these (21, 34), the number of adenomas analyzed was very small (≤	 
4). The study by Lam et al. (35) is the only one that compared protein expression in a 
relatively large number (n=20) of paired adenoma and normal mucosa samples. They used 
2-DE to resolve over 1000 proteins in the two tissue groups, and those displaying 
differential expression were then analyzed with MALDI-TOF/TOF MS. MS/MS validation 
pinpointed four proteins (ANXA3, S100A11, EIF-5A1, S100P) whose expression in 
adenomas was significantly increased. Using MS with iTRAQ 8-plex peptide labeling and 
OFFGEL fractionation allowed us to quantitatively compare protein expression in 30 
colorectal adenomas and paired samples of normal mucosa, and to investigate low-
abundance proteins that cannot be evaluated with 2-DE-based proteomics. All in all, 4325 
non-redundant protein families were quantified in our colorectal tissues (25% of which were 
identified in all 60 samples) (Table 2). And the 212 proteins we flagged as being 
significantly dysregulated in adenomas included three of the four proteins identified by Lam 
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et al. (upregulation of the fourth, EIF-5A1, failed to meet our stringent criterion for 
significance) (Table 3).  
The cell types in which these proteomic changes occur is of obvious interest since 
colorectal cancer arises from the epithelial component of the colorectal mucosa. Although 
our findings are preliminary and will naturally require validation in future studies, 51 of the 
212 proteins listed in Table 3 were "epithelial cell signature" proteins and showed 
directionally similar expression changes in colon cancer cell lines vs. HCEC. It therefore 
seems likely that their dysregulated expression in adenomas is a feature of neoplastic 
transformation of colorectal epithelial cells. However, epithelial-stromal cell interactions can 
also play important roles in tumorigenesis (20). Our approach also allowed us to identify 
101 proteins displaying adenoma-related dysregulation that were probably of stromal-cell 
origin since they were not expressed in any of the six epithelial cell lines we examined 
(Table 3). These proteins were mainly involved in immune-related processes (immune 
response, complement activation, T cell co-stimulation), which are usually not represented 
in colon epithelial cell lines. Their expression changes are likely to have important effects 
on the microenvironment of an epithelial-cell tumor.  
Our search for potential biomarkers of early-stage colorectal tumorigenesis 
focused exclusively on the 76 proteins whose expression was significantly upregulated in 
adenomas. According to the Human Protein Atlas (HPA) database (36), 69 (91%) of these 
have cancer-related features, and 16 of the 69 are already classified as candidate cancer 
biomarkers (Table 3). The HPA database contains information on protein expression in 
normal and cancer tissues, but not in those regarded as precancerous. The overlap 
between our findings and those of the HPA suggest that most protein expression changes 
identified thus far in colorectal adenocarcinomas are probably already detectable in the 
benign precursors of these lesions.  
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Supplementary Figure 6 shows the expression profiles of the 10 proteins that were 
most markedly upregulated in adenomas. This group comprised two of the four proteins 
identified by Lam et al. (35) as significantly overexpressed in adenomas. Annexin A3 
(ANXA3), for example, is at the top of our list (based on q values) (Table 3). An angiogenic 
factor that induces VEGF production via the HIF-1 pathway (37), ANXA3 belongs to a 
family of calcium-dependent, phospholipid-binding proteins involved in diverse biological 
processes, including signal transduction, inflammatory responses, membrane organization, 
and the regulation of cellular growth (38, 39). Dysregulated ANXA expression is also a 
common feature of colorectal cancer (39) and most other cancers as well (40). S100A11 
expression was also increased in these tumors, which is consistent with earlier reports (41). 
The cytosolic S100 proteins interact directly with peptides on the N-terminal domain of 
annexins (38, 42), and like the annexins, they also have diverse intracellular and 
extracellular functional roles (43).  
Among the other top ten proteins displaying adenoma-related upregulation is LDHA / 
LDHB. Their expression levels were not measured separately, but LDHA is presumably 
responsible for the increased expression observed in our adenomas. LDHB expression is in 
most cases epigenetically silenced in colon cancer cells (44, 45), whereas LDHA is over-
expressed, and its activity is maintained via the oncogenic tyrosine kinase FGFR1 (46). 
LDHA is a key player in the reversible conversion of pyruvate to lactate during aerobic 
glycolysis, a typical feature of cancer cell metabolism first described by Otto Warburg (47). 
The sodium- and potassium-coupled chloride cotransporter, SLC12A2, is expressed on the 
basolateral membrane of the normal colon epithelium, where its recruitment and activation 
are regulated by calcium and cAMP. Loss of SLC12A2 leads to impaired chloride secretion 
in the intestine (48, 49), but to our knowledge, there are no published data linking this 
protein to colon cancer. The fifth markedly over-expressed protein is SET, one of the five 
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proteins that make up the inhibitor of acetyltranferases (INHAT) complex. Two other INHAT 
components, APEX1 and ANP32A/ANP32B, were also upregulated in adenomas (albeit to 
a lesser extent than SET) (Table 3). These changes are noteworthy because INHAT binds 
directly to histones, preventing their acetylation by histone acetyl transferases (50-52), and 
loss of histone acetylation is a crucial step in gene silencing (53, 54). Thus far, INHAT’s role 
in cancer has not been widely investigated, but overexpression of the complex components 
has been observed in serous epithelial ovarian cancer (55). The upregulated expression of 
PPA1/PPA2 in our adenomas might play various roles in colorectal tumorigenesis since 
these proteins are key players in the synthesis of fatty acids, nucleotides, amino acids, and 
other essential molecules (56). The phosphoprotein nucleolin (NCL), an essential protein 
for proliferating cells (57), appears to regulate several steps in the biogenesis of ribosomes, 
including transcription, ribosome assembly, and the processing of precursor ribosomal RNA 
(58-60), all of which might be instrumental to adenoma growth. As for OCIAD2, strong 
immunoreactivity for this protein has been reported in early-stage adenocarcinomas of the 
lung and in ovarian cancers (61-63), but there are no published data linking it to colorectal 
tumorigenesis. In contrast, the secreted protein REG4, which promotes mitosis and 
enhances the motility and invasiveness of colon cancer cells, is strongly expressed in these 
cells and in the serum of patients with colorectal cancer (64-66).   
The final protein characterized by marked adenoma-related upregulation was 
SORD, a key enzyme in the polyol metabolic pathway. It was selected for validation 
studies, because although aberrant polyol pathway activity has been implicated in diabetic 
complications (67-70) and myocardial ischemia (71), the role of SORD in tumorigenesis 
was completely unknown. During the execution of this study, however, upregulated SORD 
expression was reported in prostate cancer (72) and in colorectal adenomas (21), and 
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these findings strengthened our resolve to characterize this phenomenon in colorectal 
tumorigenesis.  
Upregulated SORD expression and activity in adenomas (Figure 5) would 
enhance the production of fructose (see schematic of Supplementary Figure 5A), thereby 
increasing the generation of triose sugars and diacylglycerol (intermediates in the glycolytic 
and lipid signaling pathways, respectively). Fructose is also several times more effective 
than glucose in promoting intracellular non-enzymatic glycation (73-75), and advanced 
glycation end products may contribute to the vascular complications of diabetes and other 
pathologic conditions (67, 76-78). Whether these fructose-driven metabolic events play a 
role in the development of adenomas is unclear, but the polyol pathway was very active in 
the adenomatous cells we examined. This activity was also reflected by the concomitant 
increase of the expression of KHK (Supplementary Figure 5B), the enzyme that catalyzes 
the transformation of fructose to fructose-1-P, downstream from the polyol pathway.  
The effects of these enzymatic changes on sorbitol and fructose concentrations in 
adenomas need to be investigated in larger tissue series, but our preliminary data suggest 
that the levels of both are slightly decreased in these lesions (Supplementary Figure 5C). In 
contrast, our adenomas exhibited dramatically reduced concentrations of glucose, the initial 
substrate in the polyol pathway (Supplementary Figure 5C). Adenoma-related dysregulation 
was also noted in the expression of AKR1B1, the enzyme that converts glucose to sorbitol 
(Supplementary Figure 5B). Exploitation of the polyol pathway to divert carbon from glucose 
to other energy intermediates might provide adenomatous cells with a selective advantage 
over normal cells. This pathway might prove to be another means of tumor-related glucose 
consumption in addition to the well-known glycolytic and pentose phosphate pathways 
(Supplementary Figure 5A). Advanced cancer cells consume glucose at a much higher rate 
than normal cells, and much of their energy is generated by aerobic glycolysis rather than 
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by oxidative phosphorylation of glucose in the mitochondria (i.e., the Warburg effect) (79). 
The predominantly glycolytic phenotype of cancer cells results in low glucose levels and 
high concentrations of lactate (47, 80, 81). The relative concentrations of lactate in the three 
adenomas we tested were significantly higher than those found in matched samples of 
normal mucosa (Supplementary Figure 5C), indicating that the Warburg effect is already 
evident in precancerous colorectal lesions. Studies involving metabolic flux analysis to 
monitor the fate of isotopic tracers in in vitro and in vivo systems would provide further 
insight into the biological roles of the polyol pathway in tumorigenesis.  
 
Additional information 
The MS data have been deposited to the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository (82) with 
the dataset identifier PXD000445 and DOI 10.6019/PXD000445. Further information on 
selected PSMs, peptides and corresponding assembled proteins can be found in 
Supplementary Tables 1 (tissues) and 3 (cell lines). Supplementary Figures 7 through 17 
show spectra for the proteins identified with a single peptide (listed in Supplementary 
Tables 1 and 3).  
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FIGURE LEGENDS  
 Figure 1. Project design and iTRAQ 8plex-labeling scheme. Sample 
preparation for shotgun MS/MS and important steps in the analysis of proteomic data for 
the detection of dysregulated proteins in adenomas and colon cancer cell lines. For each 
experiment on tissue samples, iTRAQ tags were assigned to a duplicate reference (two 
identical pools of normal and adenoma samples: 113 and 114, respectively), normal tissues 
(115, 117, 119) and corresponding adenomas (116, 118, 121). The same pattern was 
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repeated in all 10 experiments. In cell line experiments, two identical pools, each 
comprising all six cell lines, were used as reference (113 and 114), and each of the 
remaining six tags was used to label a single cell line. The data analysis flow chart depicted 
in this figure is described in Experimental procedures. 
 
 Figure 2. Protein coverage with iTRAQ shotgun analysis in colorectal 
tissues. (A) Analysis of Mascot emPAI values (used as a proxy for emPAI values) revealed 
a dynamic range of protein abundance in tissues that spanned four orders of magnitude (y-
axis) and corresponded with known abundance estimates for various proteins in these 
tissues. The high/moderate-abundance proteins (e.g., ACTB, FABP5, CHGA) and low-
abundance protein (e.g., POLR3A) relatively quantified in our samples are highlighted 
relative to their mean Mascot emPAI value. (B) Distribution of reported abundance ranges 
for the proteins with ≥1 unique peptides identified in tissues, and the high-MW proteins with 
the highest number of unique peptides identified. (C) Subcellular localizations of the 
proteins identified in colorectal tissues and cell lines and (D) biological processes in which 
these proteins are involved. This analysis was performed using Scaffold and Gene 
Ontology annotations (see Experimental procedures).  
 
 Figure 3. Principal component analysis of protein expression.  Three-
dimensional principal component analysis (PCA) score plot of log2 protein expression 
intensity values for (A) tissues (normal mucosa, black; adenomas, red); (B) cell lines 
(HCEC, cyan; colon cancer cell lines, green); and (C) both. The first three principal 
components (PCs) account for 40%, 82%, and 36% of the total variance in the tissue, cell 
line, and tissue+cell line sets, respectively. PC1, the main direction of spread in the three 
groupings, reflects intergroup variance based on tissue or cell-line type (i.e., 
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normal/immortalized versus tumorous). Cell lines derived from the same patient: * SW480 
and SW620 cells; ^ HT29 and CX1 cells.  
  
 Figure 4. Analysis of the 212 proteins displaying significant tumor-related 
dysregulation. (A) Hierarchical clustering of iTRAQ abundance ratios (normal vs. 114, 
adenoma vs. 114) for the 212 proteins displaying significant adenoma-related dysregulation 
grouped tissue samples into two discrete clusters: adenoma (A) and normal (N). (B) 
Pearson’s correlation test comparing average fold changes (≥ ±0.5 log2) for the 212 
proteins (red, upregulated; blue, downregulated) in the tissue series with average log2 fold 
changes for the corresponding mRNAs measured in another set of adenoma/normal 
mucosal samples.  
 
Figure 5. Significantly upregulated SORD expression and activity in 
colorectal cell lines and adenomas. (A) Tumor-related upregulation of sorbitol 
dehydrogenase (SORD) in colon cancer cell lines was confirmed with Western blotting. The 
SORD dysregulation trend was identical to that observed with iTRAQ-based MS/MS, 
although when immunoblot results were quantified (B), the log2 fold changes were over five 
times greater than those documented in the iTRAQ study. (C) SORD protein expression 
(iTRAQ analysis) in 21 normal mucosa/adenoma tissue pairs. (D) SORD mRNA expression 
in 42 other normal mucosa/adenomas from a previous study by our group (26). Error bars 
indicate the means and 95% confidence intervals. (E) Western blots showing tumor-related 
upregulation of SORD expression in four randomly selected adenoma [A] /normal mucosa 
[N] tissue pairs of the 21 shown in panel C (see Table 1 for sample descriptions). (F) SORD 
activity also displayed tumor-related upregulation in cell lines (HT29 and SW480 versus 
HCEC cells) and tissues (adenomas versus normal mucosa). Columns show mean enzyme 
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activity measured in at least two replicates; error bars indicate standard deviations from 
means. The Western blot beneath the graph shows SORD levels measured in the extracts 
used for the enzyme activity assays. 
 
Figure 6. Anti-SORD immunostaining of colorectal cell lines and tissues.  
Consistent with proteomic data, SORD expression was (A) negligible or absent in HCECs,  
but (B) clearly expressed in the cytoplasm of HT29 cells. (C) In normal colorectal mucosa, 
SORD expression was limited to the lower portion of the epithelial crypts, where stem cells 
and highly-proliferating cells are located. Higher magnification views show staining at (D) 
the base vs. (E) mouth of colonic crypts. (F) and (G): Its expression was markedly 
increased in adenomatous glands (red arrowheads) compared with normal crypts (green 
arrowheads). Panels (H) and (I) show abundant expression of SORD in a large adenoma 
and in a cancer, respectively.  
Patient 
number Age Sex
Colon 
segment  
involved
Maximum 
lesion 
diameter 
(mm)
Paris 
classification 
# 
Pit pattern 
classification 
º
Microscopic 
appearance
Highest 
degree of 
dysplasia in 
the lesion ▪ 
No. of  lesions 
at study 
colonoscopy 
∞
No. of 
previously  
excised 
lesions ‡
1 77 M S 25 IIa+IIc IIIs - IIIL TA LGD 1 0
2 73 F A 25 IIa+IIc IIIs-IIIL TA LGD 1 2
3 59 M T 30 IIa+IIc IIIs + IIIL TA LGD 1 0
4 73 F R 50 Is IV VA LGD 1 0
5 74 M R 40 Is IV VA HGD 2 1
6 77 M C 25 IIa IIIL VA LGD 1 0
7 80 M A 40 IIa IIIL TVA LGD 1 1
8 82 M A 15 IIa IIIL VA LGD 2 0
9 73 F S 20 Ip IV TVA LGD 1 0
10 70 F C 25 IIa IIIL TVA LGD 2 0
11 63 M A 45 Is IIIL-IV TVA LGD 0 0
12 68 M A 30 IIa+Is IIIL - IV TVA  HGD 0 0
13 60 M D 30 Is IV - Vi TVA  HGD 0 0
14 55 M C 25 IIa+Is IIIL-IV SSA LGD 0 0
15 70 M A 15 Is IV TVA LGD 7 0
16 85 F S 25 Is+IIa IV TA LGD 1 1
17 66 M A 30 IIa IIIL TA HGD 2 0
18 72 M A 30 Is IV TVA HGD 2 0
19 71 M S 30 IIa IIIL TVA LGD 2 0
20 59 M R 60 Is IV-Vi TVA HGD 1 0
21 78 M A 50 Is IV - Vi TA LGD 1 0
22 75 M R 25 Is IV - Vn TVA HGD 6 0
23 73 F D 25 Is IV TA LGD 1 0
24 69 F R 90 Is+IIa IV TVA LGD 1 0
25 75 M T 18 IIa IIIL TA LGD 1 0
26 61 M A 40 Is+IIa IV TVA LGD 20 0
27 76 M S 30 Is IV - Vi TA HGD 1 0
28 78 F R 60 IIa+Is IV TVA LGD 1 1
29 89 M R 30 Is IV TA LGD 3 0
30 75 M A 50 Is IV-Vn TVA HGD/cancer 7 0
∞ This number includes the lesion included in our proteomic study
Table 1.  Characteristics of the precancerous colorectal lesions included in the study.
Abbreviations: M, male; F, female; C, cecum; A, ascending colon; T, transverse colon;  D, descending colon; S, sigmoid colon; R, rectum; 
TA, tubular adenoma; TVA, tubulovillous adenoma; VA, villous adenoma;  SSA, sessile serrated adenoma; LGD, low-grade dysplasia; HGD, 
high-grade dysplasia.
# Macroscopic appearance of neoplastic lesions was classified according to Paris Endoscopic Classification.  The Paris Endoscopic 
Classification of Superficial Neoplastic Lesions. Gastrointest Endosc 2003;58(suppl.):S3-S27
º Morphological analysis of colon crypt patterns according to the Kudo classification. Kudo S, Rubio CA, Teixeira CR, et al. Pit pattern in 
colorectal neoplasia:endoscopic magnifying view. Endoscopy 2001;33;367-7
▪ Low-grade versus high-grade dysplasia as defined by the WHO classification of tumors of the digestive system, editorial and consensus 
conference in Lyon, France, November 6-9, 1999.IARC
Total FDR (%) Total FDR (%)
Peptide spectra matches 285,929 0.2 27,922 0.4
Peptides 37,184 0.9 11,266 0.5
Proteins * 10,452 1.5 5,056 1.1
Proteins # 4,325 - 2,017 -
Proteins ^ 1,072 - 1,957 -
^ Non-redundant protein families quantified in all 60 tissues or in all 6 cell lines.
Tissues (n = 60) Cell lines (n = 6)
Table 2.  Summary of proteomics data
* Total number of proteins quantified in the 10 tissue experiments and the single 
experiment with cell lines.
# Non-redundant protein families quantified in our dataset.
UniProt accession no.* Gene name q value Average fold change (log2)
P12429 ANXA3 0.00000001 1.44
Q9UN36 NDRG2 0.00000001 -0.79
P00918 CA2 0.00000003 -2.26
P23946 CMA1 0.00000005 -1.38
P00488 F13A1 0.00000005 -1.30
Q9UBR2 CTSZ 0.00000016 -1.23
P10645 CHGA 0.00000016 -1.82
O60844 ZG16 0.00000024 -2.02
P17174 GOT1 0.00000045 -0.61
P31949 S100A11 0.00000062 1.49
P00338 ^; P07195 LDHA; LDHB 0.00000068 0.62
O60701 UGDH 0.00000104 -0.70
P55011 SLC12A2 0.00000115 0.85
O95571 ETHE1 0.00000120 -0.74
Q01105 SET 0.00000230 0.72
Q16851 UGP2 0.00000275 -0.53
Q00796 SORD 0.00000275 0.62
P20231; Q15661 TPSB2; TPSAB1 0.00000275 -1.51
Q15181; Q9H2U2 ^ PPA1; PPA2 0.00000421 0.64
Q9H3G5 CPVL 0.00000467 -0.69
P01282 VIP 0.00000722 -1.10
P07339 CTSD 0.00000856 -0.71
P19338 NCL 0.00000934 0.50
Q6UWP2 DHRS11 0.00001070 -1.20
P04066 FUCA1 0.00001240 -1.32
Q53EL6 PDCD4 0.00001270 -0.51
P07585 DCN 0.00001580 -1.36
P02511 CRYAB 0.00002720 -1.19
Q96CX2 KCTD12 0.00003590 -0.70
Q05707; P08123 COL14A1 0.00004020 -1.21
P51884 LUM 0.00004160 -0.96
Q15063 POSTN 0.00004240 -2.10
P21397 MAOA 0.00004240 -0.63
O00748 CES2 0.00004610 -0.88
Q56VL3 OCIAD2 0.00004960 0.95
Q9BYZ8 REG4 0.00004960 0.98
P55008 AIF1 0.00005650 -0.75
P50224; P50225 SULT1A3; SULT1A1 0.00005760 -0.63
O14773 TPP1 0.00006430 -0.52
Q16853 AOC3 0.00006650 -1.16
P53634 CTSC 0.00006940 -0.58
O95881 TXNDC12 0.00006940 0.55
O75795 UGT2B17 0.00006940 -1.57
O00391 QSOX1 0.00006940 -0.70
Q99538 LGMN 0.00006940 -0.63
P12111 COL6A3 0.00006990 -0.74
P80188 LCN2 0.00006990 1.32
P12956 ^ XRCC6 0.00007190 0.53
Q6NZI2 PTRF 0.00007860 -0.76
P09382 LGALS1 0.00007880 -0.84
P25815 S100P 0.00008020 3.38
Q15118 PDK1 0.00008120 -0.90
O75380 NDUFS6 0.00008650 -0.63
Q9HAW8 UGT1A10 0.00009090 -0.95
P01042 KNG1 0.00009660 -0.74
O75356 ENTPD5 0.00012385 -0.54
Table 3. Proteins displaying differential expression in adenomas vs. normal mucosa
Table 3. (continued).
Q15293 RCN1 0.00012867 0.61
P17931 LGALS3 0.00013151 -0.62
P36952 SERPINB5 0.00013151 1.31
P09211 ^ GSTP1 0.00014809 0.55
P20774 OGN 0.00015467 -1.52
Q8NBJ4 GOLM1 0.00015467 -0.51
Q16563 SYPL1 0.00015568 1.16
P04229; P13761; Q30134; 
Q9TQE0; Q9GIY3; Q29974; 
P04440; P79483
HLA-DRB1; HLA-DRB1; HLA-
DRB1; HLA-DRB1; HLA-DRB1; 
HLA-DRB1; HLA-DPB1; HLA-
DRB3  
0.00015568 -0.81
P35555 FBN1 0.00017230 -0.74
Q9H4M9; Q9NZN4; Q9H223;  EHD1; EHD2; EHD4  0.00017230 -0.56
O00754 MAN2B1 0.00017278 -0.65
B4DR31 DPYSL2 0.00018023 -0.55
P06703 ^ S100A6 0.00018025 1.18
P19801 ABP1 0.00022289 -0.50
P20042 EIF2S2 0.00022417 0.68
P51858 HDGF 0.00024151 0.56
P49959 ^ MRE11A 0.00024174 0.64
O00299 ^; Q9Y696 CLIC1; CLIC4 0.00024726 0.67
P61604 ^ HSPE1 0.00024977 0.52
O43252; O95340 PAPSS1; PAPSS2 0.00027464 -0.57
Q12765 SCRN1 0.00029349 -0.64
Q9HB40 SCPEP1 0.00030328 -0.87
P48556 PSMD8 0.00032019 0.56
O60547 GMDS 0.00034711 0.58
Q9Y6R7 FCGBP 0.00035167 -0.73
P61626 LYZ 0.00036558 0.74
Q9Y224 C14orf166 0.00038868 0.52
P01765; P01764 (Ig heavy chain V-III region TIL; Ig heavy chain V-III region VH26) 0.00038868 -0.69
Q9NVP1 DDX18 0.00038996 0.67
P80365 HSD11B2 0.00039413 -0.68
P39687; Q92688 ANP32A; ANP32B 0.00039654 0.56
Q86WA6 BPHL 0.00046215 0.52
P24298 GPT 0.00047338 -0.56
Q12874 SF3A3 0.00052166 0.50
P04899; Q14344; P63092 GNAI2; GNA13; GNAS 0.00062192 -0.51
Q15124 PGM5 0.00068593 -0.68
Q9HAW7; Q9HAW9; O60656 UGT1A7; UGT1A8; UGT1A9 0.00071202 -0.87
P19224 UGT1A6 0.00071202 -0.87
P06748 NPM1 0.00071508 0.81
Q9NUV9 GIMAP4 0.00071508 -0.89
P18283 ^ GPX2 0.00071508 0.54
P13688 CEACAM1 0.00072482 -1.06
P01591 IGJ 0.00084082 -1.10
P19823 ITIH2 0.00085565 -0.71
P01774; P01776; P01779
(Ig heavy chain V-III region POM; 
Ig heavy chain V-III region WAS; Ig 
heavy chain V-III region TUR) 
0.00085565 -0.79
P27695 ^ APEX1 0.00086971 0.54
Q9C002 NMES1 0.00087016 -0.91
Q96F85 CNRIP1 0.00088956 -1.27
Q9BPX5 ARPC5L 0.00095098 0.67
P62263 RPS14 0.00095182 0.52
Q9BY32 ITPA 0.00095634 0.51
P01625 (Ig kappa chain V-IV region Len) 0.00097041 -0.61
Table 3. (continued).
Q15582 TGFBI 0.00097041 0.90
Q07021 ^ C1QBP 0.00101874 0.76
P00738 HP 0.00102030 -0.61
O15143 ARPC1B 0.00103757 -0.50
Q03154 ACY1 0.00108571 0.60
Q9HCB6 SPON1 0.00115609 -0.89
Q96HE7 ERO1L 0.00119027 0.50
P08575 PTPRC 0.00119950 -0.52
Q9Y266 NUDC 0.00152358 0.56
P63313; P62328 TMSB10; TMSB4X 0.00159602 0.98
Q96SQ9 CYP2S1 0.00162405 0.84
Q71U36 TUBA1A 0.00162405 0.54
P00915 CA1 0.00163258 -1.18
P04844 RPN2 0.00165748 0.55
P09669 COX6C 0.00171230 -0.61
P21980 TGM2 0.00174251 -0.55
P00325 ADH1B 0.00175658 -1.18
O14745 SLC9A3R1 0.00175658 -0.51
Q9H8H3 METTL7A 0.00179938 -0.50
P61009 SPCS3 0.00186488 -0.69
Q15746; O15264; Q16539 MYLK; MAPK13; MAPK14 0.00186488 -0.53
P01876; P01877; Q92973 IGHA1; IGHA2; TNPO1 0.00191760 -1.01
P12109 COL6A1 0.00194792 -0.67
Q9BX66 SORBS1 0.00205902 -0.64
E9PGJ9 CC2D1A 0.00213982 -0.53
P49006 MARCKSL1 0.00233532 0.51
Q01524 DEFA6 0.00233532 1.60
P01620 (Ig kappa chain V-III region SIE) 0.00238585 -0.56
P36873 PPP1CC 0.00240171 0.58
Q07507 DPT 0.00240576 -1.28
P37840 SNCA 0.00261720 -0.57
P00326; P07327 ADH1C; ADH1A 0.00271753 -1.17
P22105 TNXB 0.00271753 -0.51
O95299 NDUFA10 0.00272901 -0.84
Q9NRP0 OSTC 0.00275806 0.76
P10082 PYY 0.00282902 -1.59
P21810 BGN 0.00283401 -0.66
Q8IV08 PLD3 0.00295758 -0.74
P01857; P01859; P01860; P01861 IGHG1; IGHG2; IGHG3; IGHG4 0.00343621 -0.57
P62330 ARF6 0.00343645 0.84
Q03135 CAV1 0.00346186 -0.71
P22309; P35503; P22310; P35504 UGT1A1; UGT1A3; UGT1A4; UGT1A5 0.00349148 -0.87
Q9NSU2 TREX1 0.00349148 -0.76
Q9UKY7 CDV3 0.00355684 0.79
Q7Z4V5 HDGFRP2 0.00360855 0.65
P07357 C8A 0.00372327 -0.62
Q99757 TXN2 0.00377179 -0.73
P13686 ACP5 0.00385765 -0.80
Q8WWA0 ITLN1 0.00392858 -1.30
P62861 FAU 0.00395014 0.51
P57737 CORO7 0.00401004 -0.83
P10606 COX5B 0.00412793 -0.71
Q9Y259 CHKB 0.00420774 -0.59
Q9Y2J8 PADI2 0.00435864 -0.50
O94919 ENDOD1 0.00451988 -0.80
B9A064; P0CG05; A0M8Q6 IGLL5; IGLC2; IGLC7 0.00451988 -0.56
P20039 HLA-DRB1 0.00459324 -0.82
Table 3. (continued).
P63167 ^; Q96FJ2 DYNLL1; DYNLL2 0.00468484 0.63
Q9UNN8 PROCR 0.00480932 -0.78
P07099 EPHX1 0.00486543 -0.54
P32322 PYCR1 0.00495977 0.55
Q9P0J0 NDUFA13 0.00534323 -0.60
E7EUF8; E9PFN5 EPB41L3; GSTK1 0.00539222 -0.95
O75531 BANF1 0.00560405 0.73
P26447 S100A4 0.00562754 -0.53
Q9NVJ2 ARL8B 0.00562754 0.50
Q8N752 CSNK1A1 0.00562754 0.52
P40616 ARL1 0.00583778 0.60
Q96GA7 SDSL 0.00583778 -0.82
P01275 GCG 0.00607808 -1.33
P15289 ARSA 0.00633336 -0.57
O75521 ECI2 0.00635218 -0.60
P62158 ^ CALM1; CALM2; CALM3 0.00657472 0.67
P49821 NDUFV1 0.00669319 -0.66
Q15746-5 MYLK 0.00678109 -0.51
Q96BM9 ARL8A 0.00686655 0.54
Q6UX06 OLFM4 0.00696505 1.14
P10153 RNASE2 0.00724902 -0.50
P19075 ^ TSPAN8 0.00837908 0.59
Q8WU39 PACAP 0.00837978 -0.56
P21953 BCKDHB 0.00837978 0.54
O76041 NEBL 0.00837978 0.71
Q9H4G4 GLIPR2 0.00849532 -1.10
P01766; P01767; P01768
(Ig heavy chain V-III region BRO;Ig 
heavy chain V-III region BUT; Ig 
heavy chain V-III region CAM) 
0.00895132 -0.61
Q9NR56; Q5VZF2 MBNL1; MBNL2 0.00996176 0.55
P27105 STOM 0.01083127 -0.51
P05387 RPLP2 0.01100903 0.62
Q96AB3 ISOC2 0.01164408 -0.51
O43294 TGFB1I1 0.01198321 -0.57
Q08752 PPID 0.01211602 0.55
Q96DG6 CMBL 0.01289211 -0.51
P61619 SEC61A1 0.01375705 0.59
P56381; Q5VTU8 ATP5E; ATP5EP2 0.01440856 -0.52
P14174 ^ MIF 0.01488262 0.51
P12110 COL6A2 0.01526347 -0.53
Q14956 GPNMB 0.01546825 -0.63
P46952 HAAO 0.01570996 -0.53
Q86VN1 VPS36 0.01610077 0.67
Q96S52 PIGS 0.01626862 -0.61
P15559 ^ NQO1 0.01626862 0.56
O60575 SPINK4 0.01810104 0.77
P55735 SEC13 0.01827155 0.59
P02452 COL1A1 0.01933726 -1.32
P00403 MT-CO2 0.02012815 -0.62
^ Designated candidate cancer biomarkers in the Human Protein Atlas database
* Two or more accession numbers: proteins from the same family or isoforms from the same gene. 
Boldface numbers indicate "epithelial cell signature" proteins. (See text.) 
GO ID GO Term Annotated * Significant * Up in adenomas
Down in 
adenomas Expected * elim P value *
GO:0006805 xenobiotic metabolic process † 64 21 3 18 2.8 1.70E-09
GO:0006958 complement activation, classical pathway † 74 17 0 17 3.24 1.10E-08
GO:0051552 flavone metabolic process † 5 5 0 5 0.22 1.50E-07
GO:0052696 flavonoid glucuronidation † 5 5 0 5 0.22 1.50E-07
GO:0052697 xenobiotic glucuronidation † 5 5 0 5 0.22 1.50E-07
GO:0042573 retinoic acid metabolic process † 9 6 0 6 0.39 5.00E-07
GO:0045087 innate immune response § 249 33 4 29 10.91 7.80E-07
GO:0031295 T cell costimulation § 34 10 0 10 1.49 1.10E-06
GO:0030199 collagen fibril organization  † 8 5 0 5 0.35 7.80E-06
GO:0001501 skeletal system development 54 11 1 10 2.37 1.60E-05
GO:0070208 protein heterotrimerization † 5 4 0 4 0.22 1.70E-05
GO:0050852 T cell receptor signaling pathway § 48 10 0 10 2.1 3.20E-05
* Annotated: proteins in TopGO Background list; Significant: 212 dysregulated proteins of Table 3; Expected: Number of 
signifcant proteins expected to map to the GO term if the significant proteins were randomly distributed over all GO terms. elim P 
value: P value from the elim method (ref. no. 25). Only processes with an elim P value < 1.0E-04 are shown.
Table 4.  Gene Ontology (GO) biological processes enriched in the set of 212 proteins whose expression displayed 
adenoma-related dysregulation (see Table 3).
†	  Processes that were also among the top 12 processes displaying enrichment in a larger set of 621 dysregulated proteins 
selected with less stringent criteria (q value ≤ 0.2; average log2 fold change ≥ ± 0.5; see Results section for details); § processes 
that shared a common GO ancestor (immune system process) with the process displaying most significant enrichment in the 
larger set. 
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